A Multicenter, Randomized, Open-Label Study to Compare the Effects of Gemigliptin Add-on or Escalation of Metformin Dose on Glycemic Control and Safety in Patients with Inadequately Controlled Type 2 Diabetes Mellitus Treated with Metformin and SGLT-2 Inhibitors (SO GOOD Study)

Table 3

Adverse events.

	Metformin ()	Gemigliptin ()
Serious adverse events	0	0
Drug withdrawn due to adverse event	0	1 (2.70)
Adverse events
Hypoglycemia	0	0
Pancreatitis	0	0
Genital infection	0	0
Urinary tract infection	0	0
Liver enzyme elevation^a	0	0
Creatinine elevation^b	1 (2.63)	0
Leukocytosis^c	0	0
Urticaria	0	1 (2.70)
Others
Dim eyes	1 (2.63)	0
Diabetic retinopathy	1 (2.63)	0
Diabetic neuropathy	0	1 (2.70)
Herpes zoster	0	1 (2.70)
Colon polyps	1 (2.63)	0

Values are presented as number (%). ^aAST or ALT 3 times higher than the upper limit of the normal range. ^b mg/dL. ^cWhite blood cell . AST: aspartate aminotransferase; ALT: alanine aminotransferase.